What is Boundless Bio?
Boundless Bio is a next-generation precision oncology enterprise dedicated to transforming the treatment landscape for patients suffering from oncogene amplified cancers. By focusing on the biology of extrachromosomal DNA (ecDNA), the company is pioneering a novel therapeutic class designed to address the limitations of traditional cancer treatments. This scientific focus positions the firm at the intersection of advanced genomics and drug development, providing a distinct competitive advantage in the biotechnology market. The company's lifecycle has evolved from early-stage innovation to a mature enterprise-level entity, supported by a robust syndicate of life science investors.
How much funding has Boundless Bio raised?
Boundless Bio has raised a total of $251.4M across 3 funding rounds:
Series A
$46.4M
Series B
$105M
Series C
$100M
Series A (2019): $46.4M with participation from GT Healthcare Capital Partners, Boxer Capital, Vertex Ventures, Alexandria Venture Investments, ARCH Venture Partners, and City Hill Ventures
Series B (2021): $105M led by Wellington Management, PFM Health Sciences, RA Capital Management, Surveyor Capital, Redmile Group, Nextech Invest, Logos Capital, and Fidelity Management & Research Company
Series C (2023): $100M supported by Sectoral Asset Management, RA Capital Management, and Bayer
Key Investors in Boundless Bio
Sectoral Asset Management
Sectoral Asset Management is an investment advisor specializing in managing equities globally within the healthcare sector, with a strong track record in biotech.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies.
Bayer
Bayer is a global life science enterprise with core competencies in healthcare and agriculture, focusing on innovative medicines and oncology research.
What's next for Boundless Bio?
With the infusion of capital from its latest financing, Boundless Bio is well-positioned to accelerate its clinical development pipeline and expand its research capabilities. The strategic focus will likely remain on validating its ecDNA-targeting therapies in human trials, a critical milestone for any oncology-focused biotechnology firm. As the company transitions into its next phase of growth, it will continue to leverage its deep scientific expertise and institutional backing to address the high unmet medical needs of patients with aggressive, oncogene-driven malignancies. The firm's ability to maintain strong investor interest suggests a clear path toward potential commercialization and long-term value creation in the global healthcare market.
See full Boundless Bio company page
